aTyr Pharma (ATYR) News Today $0.84 +0.01 (+1.42%) Closing price 04:00 PM EasternExtended Trading$0.84 0.00 (-0.16%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATYR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Leerink Partners Remains a Hold on aTyr Pharma (ATYR)October 4 at 5:48 PM | theglobeandmail.comaTyr Pharma, Inc. (NASDAQ:ATYR) Receives $23.25 Consensus PT from AnalystsOctober 4 at 2:23 AM | americanbankingnews.comaTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower – Hagens BermanOctober 3, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYROctober 3, 2025 | prnewswire.comaTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Rating of "Hold" by AnalystsOctober 1, 2025 | marketbeat.comaTyr Pharma reports clinical benefit for efzofitimod across multiple diseasesSeptember 30, 2025 | msn.comaTyr Pharma (ATYR) Price Target Decreased by 49.82% to 10.31September 30, 2025 | msn.comaTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens BermanSeptember 30, 2025 | globenewswire.comaTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025September 30, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYRSeptember 28, 2025 | prnewswire.comaTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens BermanSeptember 25, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYRSeptember 24, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYRSeptember 23, 2025 | prnewswire.comaTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens BermanSeptember 23, 2025 | prnewswire.comaTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens BermanSeptember 22, 2025 | globenewswire.comaTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens BermanSeptember 19, 2025 | prnewswire.comTop 3 Health Care Stocks That May Explode In SeptemberSeptember 19, 2025 | benzinga.comCantor Fitzgerald Expects Stronger Earnings for aTyr PharmaSeptember 19, 2025 | marketbeat.comLeerink Partnrs Has Negative View of aTyr Pharma Q3 EarningsSeptember 19, 2025 | marketbeat.comaTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens BermanSeptember 18, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYRSeptember 18, 2025 | prnewswire.comHC Wainwright Forecasts Stronger Earnings for aTyr PharmaSeptember 18, 2025 | marketbeat.comaTyr Pharma (NASDAQ:ATYR) Downgraded by Jones Trading to HoldSeptember 18, 2025 | marketbeat.comaTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYRSeptember 18, 2025 | prnewswire.comFoundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial ResultsSeptember 17, 2025 | markets.businessinsider.comAssessing aTyr Pharma (ATYR) Valuation as Investors Weigh Recent Stock Swings and Future ProspectsSeptember 17, 2025 | finance.yahoo.comFoundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma's Phase 3 Clinical Trial ResultsSeptember 17, 2025 | globenewswire.comaTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FITÔ Study Failure Drives Shares 80% Lower -- Hagens BermanSeptember 17, 2025 | prnewswire.comaTyr Pharma (NASDAQ:ATYR) Downgraded by Leerink Partnrs to HoldSeptember 17, 2025 | marketbeat.comWells Fargo Downgrades aTyr Pharma (ATYR)September 17, 2025 | msn.comaTyr Pharma (NASDAQ:ATYR) Sets New 52-Week Low Following Analyst DowngradeSeptember 16, 2025 | marketbeat.comaTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FITâ„¢ Study Failure Drives Shares 80% Lower -- Hagens BermanSeptember 16, 2025 | globenewswire.comaTyr Pharma (NASDAQ:ATYR) Given Equal Weight Rating at Wells Fargo & CompanySeptember 16, 2025 | marketbeat.comINVESTOR ALERT: Investigation of aTyr Pharma, Inc. (ATYR) Announced by Holzer & Holzer, LLCSeptember 16, 2025 | globenewswire.comaTyr Pharma (NASDAQ:ATYR) Lowered to Neutral Rating by HC WainwrightSeptember 16, 2025 | marketbeat.comaTyr Pharma's (ATYR) Market Perform Rating Reiterated at Leerink PartnersSeptember 16, 2025 | marketbeat.comaTyr Pharma (NASDAQ:ATYR) Rating Lowered to "Neutral" at Cantor FitzgeraldSeptember 16, 2025 | marketbeat.comaTyr Pharma stock crashes on Phase III pulmonary sarcoidosis failSeptember 16, 2025 | finance.yahoo.comaTyr Pharma, Inc. (ATYR) Special Call - SlideshowSeptember 16, 2025 | seekingalpha.comaTyr Pharma shares plunge after Phase 3 trial misses primary goalSeptember 15, 2025 | msn.comaTyr hits record low as lung disease drug fails in late-stage trialSeptember 15, 2025 | reuters.comATyr Pharma's Lead Program Misses Main Endpoint in Phase 3 StudySeptember 15, 2025 | marketwatch.comATyr Pharma Shares Plummet More Than 80% After Study FailureSeptember 15, 2025 | marketwatch.comaTyr Pharma stock tanks after missing main goal in lung disease studySeptember 15, 2025 | msn.comaTyr Pharma: Moving To Hold On Release Of Pulmonary Sarcoidosis Treatment DataSeptember 15, 2025 | seekingalpha.comATyr Pharma, Inc. (ATYR) Announces Top Line Results For The Phase III EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis (Transcript)September 15, 2025 | seekingalpha.comaTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYRSeptember 15, 2025 | businesswire.comBREAKING: aTyr Pharma Shares Plummet 80%; Investors Should Contact Block & Leviton to Potentially Recover LossesSeptember 15, 2025 | globenewswire.comaTyr Pharma's lung disease drug misses main goal in late-stage trialSeptember 15, 2025 | reuters.comaTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary SarcoidosisSeptember 15, 2025 | globenewswire.com Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATYR Media Mentions By Week ATYR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATYR News Sentiment▼0.250.55▲Average Medical News Sentiment ATYR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATYR Articles This Week▼74▲ATYR Articles Average Week Get the Latest News and Ratings for ATYR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for aTyr Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Alpha Teknova News Capricor Therapeutics News Replimune Group News Canopy Growth News Alector News Mereo BioPharma Group News Upexi News Candel Therapeutics News Aldeyra Therapeutics News scPharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATYR) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
